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We confirmed a bacteremic typhoid fever incidence of
3.9 episodes/1,000 person-years during fever surveillance
in a Dhaka urban slum. The relative risk for preschool chil-
dren compared with older persons was 8.9. Our regression
model showed that these children were clinically ill, which
suggests a role for preschool immunization. 
T
yphoid fever is a major cause of illness; the global
incidence in 2000 was an estimated 21,650,974 cases
with 216,510 deaths (1). The cause of typhoid fever,
Salmonella enterica subspecies enterica serotype Typhi (S.
Typhi), is both waterborne and foodborne, with an annual
incidence approaching 1% in disease-endemic areas (2–4).
Peak incidence is reported to occur in children 5–15 years
of age; however, in regions where the disease is highly
endemic, children <5 years of age may have among the
highest infection rates (1,4–6). Population-based data are
limited (1) and would be helpful for refining estimates of
the impact of disease  and for identifying age groups at
highest risk, thereby making it possible to optimize vacci-
nation strategies (7,8).
Data on disease severity and sequelae can contribute to
estimating the impact of disease. Most complications—
including intestinal perforation and peritonitis,
encephalopathy, intestinal hemorrhage, hepatospleno-
megaly, vomiting, and diarrhea (4,9)—are late onset.
Whether children <5 years of age (preschool children)
have silent infection or clinical disease is controversial
(4,5,10), which has important implications for both case
management and prevention. We report our findings from
prospective, population-based active surveillance.
The Study
Since 1998, the ICDDR,B Centre for Health and
Population Research has operated a surveillance and inter-
vention site in Kamalapur, an urban slum in Dhaka,
Bangladesh. We initiated fever surveillance for dengue
fever and dengue hemorrhagic fever in August 2000. To
identify treatable causes of fever, we obtained blood cul-
tures from December 6, 2000, to October 8, 2001. 
The community comprises 7 geographic strata, repre-
senting 379 clusters. We selected the surveillance cohort
by using stratified cluster randomization and obtained
informed written consent from all households. 
Field research assistants screened household members
for fever in their homes once weekly with a standardized
questionnaire. We defined fever as >3 consecutive febrile
days (reported) for persons >5 years of age, or any duration
of fever for preschool children (<5 years of age). This def-
inition facilitated detection of dengue fever. Field research
assistants referred febrile participants to our field clinic,
where study physicians confirmed fever and collected clin-
ical data by using a standard form. Patients with an axillary
temperature of >38°C were designated as febrile. After col-
lecting blood for serologic tests of dengue and dengue
hemorrhagic fever, we collected an additional 1 mL of
blood from preschool children and >3 mL from older
persons for culture. 
Blood cultures were transported within 2 hours to our
clinical microbiology laboratory (12 km from the field
clinic). Specimens were processed by using standard meth-
ods with in-tube lysis centrifugation (Wampole isolator
1.5, Carter-Wallace, Inc., Cranbury, NJ, USA), plated on
blood, chocolate, and MacConkey agar and incubated at
37°C for 16 to 18 hours. Colonies were evaluated with bio-
chemical tests and confirmed by serologic identification
with commercial antisera (Denka, Sieken, Co., Ltd.,
Tokyo, Japan). Antimicrobial susceptibility was deter-
mined by disk diffusion using standard NCCLS methods
(11). 
We confirmed typhoid fever if we isolated S. Typhi
from blood during a febrile episode. Febrile controls were
culture-negative for S.  Typhi, Paratyphi, or Salmonella
group D during fever. 
If S. Typhi was isolated, then we treated the infection
with 14 days of standard therapy, adjusting for antimicro-
bial susceptibility. First-line drugs were amoxicillin (40
mg/kg up to 1,500 mg orally divided 3 times daily) or cot-
rimoxazole (10 mg/kg trimethoprim divided into 2 daily
doses). When patients remained febrile after 72 hours or
new danger signs (e.g., lethargy, inability to drink,
cyanosis, convulsions), developed, treatment was consid-
ered to have failed. We treated treatment failure in persons
>12 years of age with ciprofloxacin (500 mg orally twice a
day) and referred younger patients to the hospital. We
defined recovery as >7 consecutive afebrile days after
completing therapy. 
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*ICDDR,B Centre for Health and Population Research, Dhaka,
BangladeshStatistical analysis was performed by using Stata/SE
Release 8.2 (Stata Statistical Software: Release 8.0. 2003,
Stata Corporation, College Station, TX, USA). Incidence
was determined by dividing the number of cases by per-
son-years of observation, with calculation of exact 95%
confidence intervals (CIs). Univariate analysis was per-
formed by using 2-by-2 tables for relative odds (RO) and
95% CIs. We obtained p values by using the Fisher 2-tailed
exact test. Multivariate modeling was conducted by step-
wise forward logistic regression, using all covariates sig-
nificantly associated with typhoid fever in univariate
analysis. Covariates that were significant when age, sex,
and geographic location were controlled for, were retained
in the final model. We adjusted models for clustering of
repeat patient visits and tested for goodness-of-fit with
either Pearson or Hosmer-Lemeshow methods (12).
Research Review and Ethical Review Committees of
ICDDR,B approved this study. 
During the study period, we took blood for culture from
888 (99.9%) of 889 eligible study participants; 54 (6.1%)
reported prior medication exposure. All specimens had
adequate volume. A microorganism was isolated from 65
(7.3%) cultures. Isolation rates were highest in winter. No
positive culture reported >1 organism (Table 1), nor did
any culture-positive patient have laboratory-confirmed
dengue. 
S. Typhi was isolated from 26 preschool children
(Figure 1) and 23 older study participants (age range 10
months–50 years, median 4.0 years [95% CI 3.0–8.0]).
There were 1,393 person-years of observation for pre-
school children and 11,014 for others. Overall, typhoid
fever incidence was 3.9 episodes/1,000 person-years.
Typhoid fever incidence among preschool children was
18.7 episodes/1,000 person-years and 2.1 episodes/1,000
person-years among older participants. The incidence rate
difference between the 2 age groups was 16.6 cases/1,000
person-years (95% CI 9.4–23.8; p < 0.001). Preschool chil-
dren’s relative risk for typhoid fever was thus 8.9 (95% CI
4.9–16.4). Typhoid fever among preschool children varied
by age, with 4% in the first year of life and 85% occurring
in those 2 to 4 years of age (Figure 2).
We investigated surveillance bias resulting from fever
definition differences between age groups (4). Preschool
children’s mean fever duration (days) prior to visiting the
clinic was 4.0 (95% CI 3.2–4.8) and other patients’ mean
duration was 4.9 (95% CI 2.9–6.8, p = 0.37). We collected
84.6% of preschool specimens and 78.3% of others’after 3
febrile days, and 96.2% and 86.7%, respectively, by day 7. 
Amultivariate model showed that typhoid fever patients
were more likely than febrile controls to be preschool age
(RO 2.04; 95% CI 1.09–3.82; p = 0.03), have >3 days of
fever (RO 2.55; 95% CI 1.16–5.63; p = 0.02), have temper-
ature >39°C (RO 1.95; CI 1.01–3.80; p = 0.04), and have
mental status changes (RO 3.94; CI 1.98–7.81; p < 0.02).
Another model indicated preschool typhoid fever patients
were significantly more likely than older patients to have
fever  >39°C (RO 1.62; CI 1.21– 2.17), mental status
changes (RO 3.54; CI 2.25–5.55), and crepitations (rales)
on auscultation (RO 4.44; CI 3.11–6.33).
All patients with culture-confirmed typhoid fever
recovered, except for 1 child with tuberculosis. Four adults
required ciprofloxacin. No hospitalizations, complications,
or deaths occurred among confirmed typhoid fever
patients.
In vitro antimicrobial susceptibility testing (Table 2)
showed a high prevalence of ampicillin, cotrimoxazole,
and chloramphenicol resistance, with 27 isolates (55.1%)
resistant to all 3; ceftriaxone resistance was found in iso-
lates from 1 preschool child. Routine nalidixic acid testing
was not performed, following NCCLS 2000 guidelines. 
Conclusions
Our data indicate a high infection ratio in this urban
population, which is highest among preschool children.
These ratios are comparable to recent regional reports
(4,6,13) and indicate that typhoid fever in preschool chil-
dren may be underappreciated. That preschool children
have 8.9 times the risk for S. Typhi infection as older per-
sons corroborates age-specific rates in highly disease-
endemic areas (1). The antimicrobial susceptibility data
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Figure 1. Distribution of typhoid fever by age. indicate high ratios of in vitro resistance to standard
antimicrobial agents, with a high prevalence of multidrug
resistance. 
The degree of illness of preschool children is controver-
sial; some report benign bacteremia (5,14) and others have
found clinical illness (4,13). Our multivariate model shows
that preschool children are clinically ill. Coexisting condi-
tions, particularly pneumonia, are not only more common
in preschool typhoid fever patients but also may result in
misclassification and underreporting, as well as contribute
to a worsening cycle of repeated infection and deaths.
Future studies should explore these issues in this age
group. 
Substantial clinical illness among preschool children
argues the need for them to be enrolled in vaccination pro-
grams. The age-specific infection rates suggest vaccination
in the first year of life, integrating with existing Expanded
Programme on Immunization (EPI) schedules. This prac-
tice would require either a polysaccharide protein-conju-
gate vaccine to stimulate T-cell–dependent responses (15)
or a live attenuated oral vaccine, since T-cell–independent
responses do not mature until the child is 18–24 months of
age. 
The limitations of this study could result in an underes-
timate of the incidence of typhoid fever. First, this study
was not designed to measure typhoid fever incidence or
disease impact. The surveillance program was designed to
identify dengue. Thus, febrile episodes for young children
were defined differently than for older persons. Although
we did not find evidence of preferential selection for
young children, future studies may adopt a common fever
definition. Second, the blood volume examined, though
not inadequate, may not have been optimal. Third, blood
culture sensitivity is relatively low, estimated at 25%–50%
(1). Fourth, the 6.1% estimate of earlier medicine exposure
may be an underestimate, as we did not validate these
reports. If these agents were antimicrobial, the number of
serovar Typhi isolates recovered from peripheral blood
would be reduced. Fifth, we had only 10 months of obser-
vation and therefore did not attempt an estimate of disease
impact, adjustments for blood culture sensitivity, or expo-
sure to antimicrobial agents. Ours is thus a conservative
estimate of incidence. Further observation should allow
the impact of disease to be estimated. 
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